Revive Therapeutics Included in First Psychedelic Exchange Traded Fund

by rvvadmin | Jan 22, 2021 | 2021

TORONTO, Jan. 22, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it...

Revive Therapeutics Announces Upsize to Previously Announced Bought Deal Offering

by rvvadmin | Jan 21, 2021 | 2021

TORONTO, Jan. 21, 2021  – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is...

Revive Therapeutics Announces $10 Million Bought Deal Offering of Units

by rvvadmin | Jan 20, 2021 | 2021

TORONTO, Jan. 20, 2021  – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is...

Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

by rvvadmin | Jan 14, 2021 | 2021

TORONTO, Jan. 14, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has...

Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

by rvvadmin | Dec 31, 2020 | 2020

TORONTO, Dec. 31, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the...